Search

Your search keyword '"Barba, Maddalena"' showing total 9 results
Start Over Author "Barba, Maddalena" Journal oncotarget
9 results on '"Barba, Maddalena"'

1. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience

Author

Vici, Patrizia, primary, Pizzuti, Laura, additional, Michelotti, Andrea, additional, Sperduti, Isabella, additional, Natoli, Clara, additional, Mentuccia, Lucia, additional, Lauro, Luigi Di, additional, Sergi, Domenico, additional, Marchetti, Paolo, additional, Santini, Daniele, additional, Magnolfi, Emanuela, additional, Iezzi, Laura, additional, Moscetti, Luca, additional, Fabbri, Agnese, additional, Cassano, Alessandra, additional, Grassadonia, Antonino, additional, Omarini, Claudia, additional, Piacentini, Federico, additional, Botticelli, Andrea, additional, Bertolini, Ilaria, additional, Scinto, Angelo Fedele, additional, Zampa, Germano, additional, Mauri, Maria, additional, D’Onofrio, Loretta, additional, Sini, Valentina, additional, Barba, Maddalena, additional, Maugeri-Saccà, Marcello, additional, Rossi, Ernesto, additional, Landucci, Elisabetta, additional, Tomao, Silverio, additional, Alberti, Antonio Maria, additional, Giotta, Francesco, additional, Ficorella, Corrado, additional, Adamo, Vincenzo, additional, Russo, Antonio, additional, Lorusso, Vito, additional, Cannita, Katia, additional, Barni, Sandro, additional, Laudadio, Lucio, additional, Greco, Filippo, additional, Garrone, Ornella, additional, Giulia, Marina Della, additional, Marolla, Paolo, additional, Sanguineti, Giuseppe, additional, Cocco, Barbara Di, additional, Ciliberto, Gennaro, additional, Maria, Ruggero De, additional, and Gamucci, Teresa, additional

Published
2017
Full Text
View/download PDF

2. Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial

Author

Moscetti, Luca, primary, Fabbri, Maria Agnese, additional, Natoli, Clara, additional, Vici, Patrizia, additional, Gamucci, Teresa, additional, Sperduti, Isabella, additional, Iezzi, Laura, additional, Iattoni, Elena, additional, Pizzuti, Laura, additional, Roma, Carmine, additional, Vaccaro, Angela, additional, D’Auria, Giuliana, additional, Mauri, Mariella, additional, Mentuccia, Lucia, additional, Grassadonia, Antonino, additional, Barba, Maddalena, additional, and Ruggeri, Enzo Maria, additional

Published
2017
Full Text
View/download PDF

3. Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting

Author

Pizzuti, Laura, primary, Natoli, Clara, additional, Gamucci, Teresa, additional, Mauri, Mariella, additional, Sergi, Domenico, additional, Di Lauro, Luigi, additional, Paoletti, Giancarlo, additional, Ruggeri, Enzo, additional, Iezzi, Laura, additional, Sperduti, Isabella, additional, Mentuccia, Lucia, additional, Fabbri, Agnese, additional, Maugeri-Saccà, Marcello, additional, Moscetti, Luca, additional, Barba, Maddalena, additional, and Vici, Patrizia, additional

Published
2017
Full Text
View/download PDF

4. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer

Author

Benedetto, Anna Di, primary, Mottolese, Marcella, additional, Sperati, Francesca, additional, Ercolani, Cristiana, additional, Lauro, Luigi Di, additional, Pizzuti, Laura, additional, Vici, Patrizia, additional, Terrenato, Irene, additional, Sperduti, Isabella, additional, Shaaban, Abeer M., additional, Sundara-Rajan, Sreekumar, additional, Barba, Maddalena, additional, Speirs, Valerie, additional, De Maria, Ruggero, additional, and Maugeri-Saccà, Marcello, additional

Published
2016
Full Text
View/download PDF

5. “Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome

Author

Vici, Patrizia, primary, Pizzuti, Laura, additional, Sperduti, Isabella, additional, Frassoldati, Antonio, additional, Natoli, Clara, additional, Gamucci, Teresa, additional, Tomao, Silverio, additional, Michelotti, Andrea, additional, Moscetti, Luca, additional, Gori, Stefania, additional, Baldini, Editta, additional, Giotta, Francesco, additional, Cassano, Alessandra, additional, Santini, Daniele, additional, Giannarelli, Diana, additional, Di Lauro, Luigi, additional, Corsi, Domenico Cristiano, additional, Marchetti, Paolo, additional, Sini, Valentina, additional, Sergi, Domenico, additional, Barba, Maddalena, additional, Maugeri-Saccà, Marcello, additional, Russillo, Michelangelo, additional, Mentuccia, Lucia, additional, D’Onofrio, Loretta, additional, Iezzi, Laura, additional, Scinto, Angelo Fedele, additional, Da Ros, Lucia, additional, Bertolini, Ilaria, additional, Basile, Maria Luisa, additional, Rossi, Valentina, additional, De Maria, Ruggero, additional, and Montemurro, Filippo, additional

Published
2016
Full Text
View/download PDF

6. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis

Author

Vici, Patrizia, primary, Benedetto, Anna Di, additional, Ercolani, Cristiana, additional, Pizzuti, Laura, additional, Lauro, Luigi Di, additional, Sergi, Domenico, additional, Sperati, Francesca, additional, Terrenato, Irene, additional, Dattilo, Rosanna, additional, Botti, Claudio, additional, Fabi, Alessandra, additional, Ramieri, Maria Teresa, additional, Mentuccia, Lucia, additional, Marinelli, Camilla, additional, Iezzi, Laura, additional, Gamucci, Teresa, additional, Natoli, Clara, additional, Vitale, Ilio, additional, Barba, Maddalena, additional, Mottolese, Marcella, additional, De Maria, Ruggero, additional, and Maugeri-Saccà, Marcello, additional

Published
2015
Full Text
View/download PDF

7. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy

Author

Vici, Patrizia, primary, Mottolese, Marcella, additional, Pizzuti, Laura, additional, Barba, Maddalena, additional, Sperati, Francesca, additional, Terrenato, Irene, additional, Benedetto, Anna Di, additional, Natoli, Clara, additional, Gamucci, Teresa, additional, Angelucci, Domenico, additional, Ramieri, Maria Teresa, additional, Lauro, Luigi Di, additional, Sergi, Domenico, additional, Bartucci, Monica, additional, Dattilo, Rosanna, additional, Pagliuca, Alfredo, additional, Maria, Ruggero De, additional, and Maugeri-Saccà, Marcello, additional

Published
2014
Full Text
View/download PDF

8. p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab

Author

Vici, Patrizia, primary, Sperati, Francesca, additional, Maugeri-Saccà, Marcello, additional, Melucci, Elisa, additional, Benedetto, Anna Di, additional, Lauro, Luigi Di, additional, Pizzuti, Laura, additional, Sergi, Domenico, additional, Terrenato, Irene, additional, Esposito, Luca, additional, Iannuzzi, Carmelina Antonella, additional, Pasquale, Raffaella, additional, Botti, Claudio, additional, Fuhrman, Barbara, additional, Giordano, Antonio, additional, Mottolese, Marcella, additional, and Barba, Maddalena, additional

Published
2014
Full Text
View/download PDF

9. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.

Author

Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Sperduti I, Shaaban AM, Sundara-Rajan S, Barba M, Speirs V, De Maria R, and Maugeri-Saccà M

Subjects
Adult, Aged, Aged, 80 and over, Breast Neoplasms, Male mortality, Breast Neoplasms, Male pathology, Carcinogenesis genetics, Carcinoma, Ductal, Breast mortality, Carcinoma, Ductal, Breast pathology, Hippo Signaling Pathway, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Ki-67 Antigen metabolism, Male, Middle Aged, Neoplasm Grading, Phenotype, Proportional Hazards Models, Rare Diseases mortality, Rare Diseases pathology, Receptors, Steroid metabolism, Retrospective Studies, Signal Transduction genetics, Tissue Array Analysis, Trans-Activators, Transcription Factors, Transcriptional Coactivator with PDZ-Binding Motif Proteins, YAP-Signaling Proteins, Adaptor Proteins, Signal Transducing metabolism, Breast Neoplasms, Male genetics, Carcinoma, Ductal, Breast genetics, Connective Tissue Growth Factor metabolism, Gene Expression Regulation, Neoplastic, Intracellular Signaling Peptides and Proteins metabolism, Phosphoproteins metabolism, Protein Serine-Threonine Kinases metabolism, Rare Diseases genetics
Abstract

Male breast cancer (MBC) is a rare disease and its biology is poorly understood. Deregulated Hippo pathway promotes oncogenic functions in female breast cancer. We herein investigated the expression of the Hippo transducers TAZ/YAP and their target CTGF in MBC. Tissue microarrays containing samples from 255 MBC patients were immunostained for TAZ, YAP and CTGF. One hundred and twenty-nine patients were considered eligible. The Pearson's Chi-squared test of independence was used to test the association between categorical variables. The correlation between TAZ, YAP and CTGF was assessed with the Pearson's correlation coefficient. The Kaplan-Meier method and the log-rank test were used for estimating and comparing survival curves. Cox proportional regression models were built to identify variables impacting overall survival. Statistical tests were two-sided. Tumors were considered to harbor active TAZ/YAP-driven gene transcription when they co-expressed TAZ, or YAP, and CTGF. Patients whose tumors had the TAZ/CTGF and YAP/CTGF phenotypes experienced shorter overall survival compared with their negative counterparts (log rank p = 0.036 for both). TAZ/CTGF and YAP/CTGF tumors were associated with decreased survival in patients with invasive ductal carcinomas, G3 tumors, hormone receptor-positive tumors, and tumors with elevated Ki-67. Multivariate analyses confirmed that the TAZ/CTGF and YAP/CTGF phenotypes are independent predictors of survival (HR 2.03, 95% CI: 1.06-3.90, p = 0.033; and HR 2.00, 95% CI: 1.04-3.84, p = 0.037 respectively). Comparable results were obtained when excluding uncommon histotypes (TAZ/CTGF: HR 2.34, 95% CI: 1.16-4.73, p = 0.018. YAP/CTGF. HR 2.36, 95% CI: 1.17-4.77, p = 0.017). Overall, the TAZ/YAP-driven oncogenic program may be active in MBC, conferring poorer survival., Competing Interests: The authors declare no conflicts of interest.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results